ESMO Congress | Conference

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

October 1st 2020

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Apalutamide Maintains Health-Related QoL Among Men With Nonmetastatic CRPC

September 25th 2020

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.

Dr. Nixon on the Role of MSI in Cancer

September 24th 2020

Andrew B. Nixon, PhD, MBA, discusses the role of microsatellite instability in cancer.

Dr. Grivas on the Subgroup Analyses of the JAVELIN Bladder 100 Trial in Advanced Urothelial Cancer

September 24th 2020

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBC

September 24th 2020

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020

Erika P. Hamilton, MD, discusses the final overall survival results from the randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Nivolumab/Chemo Improves PFS, Elicits Durable Responses in Gastric/GEJ Cancers

September 21st 2020

The addition of nivolumab to chemotherapy resulted in a statistically significant improvement in progression-free survival and elicited higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

September 21st 2020

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

September 21st 2020

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC

September 21st 2020

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

September 21st 2020

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma

September 21st 2020

First-line treatment with the combination of nivolumab and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma versus chemotherapy alone.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

Durvalumab/Tremelimumab Shows Modest Activity in Advanced NETs With GEP and Lung Origins

September 21st 2020

The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins.

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

September 21st 2020

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

Cabozantinib Combo Induces Clinical Activity in Advanced ccRCC

September 21st 2020

Treatment with cabozantinib in combination with atezolizumab demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma.